Skip to main content

RNAi / siRNA Deal Benchmarks in Oncology

Median Upfront
$297M
Range: $165M - $419M
Total Deal Value
$1.9B
Range: $1.2B - $2.5B
Royalty Rate
12.3% - 20.1%
Tiered up to 24.1%
Dev Milestones
$397M
Range: $265M - $531M
Model Your Deal

Market Analysis

RNAi / siRNA therapies in oncology have seen significant M&A and licensing activity in recent years. Based on analysis of 1,500+ verified transactions, the median upfront payment for a Phase 2 rnai / sirna asset in oncology is $297M, with total deal values reaching $1.9B. Development milestones average $397M, while regulatory milestones contribute $634M.

The oncology rnai / sirna landscape is characterized by high competitive intensity with numerous active programs and a rapidly evolving standard of care. ADCs, bispecifics, and radiopharmaceuticals continue to drive premium valuations across solid and hematologic tumors. The recommended deal structure allocates approximately 16% to upfront payments and 84% to milestones, reflecting the risk-reward profile at the Phase 2 stage.

Royalty rates for rnai / sirna oncology deals range from 12.3% to 20.1% at the base tier, with tiered escalation reaching 16.3%-24.1% on blockbuster sales. Commercial milestones averaging $555M further reward successful market penetration.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the typical upfront for a rnai / sirna oncology licensing deal?
Based on our analysis, Phase 2 rnai / sirna licensing deals in oncology average $297M in upfront payments, with a range of $165M to $419M depending on data quality, competitive positioning, and territorial scope.
What is the total deal value for rnai / sirna oncology transactions?
The median total deal value for Phase 2 rnai / sirna assets in oncology is $1.9B, ranging from $1.2B to $2.5B. This includes development milestones ($397M), regulatory milestones ($634M), and commercial milestones ($555M).
What royalty rates are standard for rnai / sirna deals in oncology?
Base royalty rates for rnai / sirna oncology transactions range from 12.3% to 20.1%, with tiered escalations reaching 16.3%-24.1% on peak sales. Rates are influenced by mechanism differentiation, competitive landscape, and territorial scope.
How are milestones structured in rnai / sirna oncology deals?
RNAi / siRNA oncology deals allocate approximately 84% of total deal value to milestones. Development milestones ($397M) make up the largest share, followed by commercial milestones ($555M) and regulatory milestones ($634M).
PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Related Benchmarks

Small Molecule in Oncology

View

Monoclonal Antibody in Oncology

View

RNAi / siRNA in Neurology

View

RNAi / siRNA in Cardiovascular

View

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.

Start Calculating
For Funds & Advisors

Need the full deal landscape?

The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.

Configure Brief — $2,500All-inclusive · White-label · Walkthrough included